| SEGMENT INFORMATION |
NOTE
13 - SEGMENT INFORMATION
The Company has one operating and reporting segment, that develops, manufactures and markets products for the treatment of carotid artery
disease and other vascular disease, including the Company’s proprietary CGuard™ stent platform. The Company’s Chief
Operating Decision Maker (“CODM”), who is the chief executive officer, evaluates the Company’s performance based on
its internal reporting which is consistent with the presentation in the Company’s consolidated financial statements. Accordingly,
our CODM uses consolidated net loss to measure segment profit or loss, allocate resources, and assess performance.
The
CODM examines, within each operational function, the employee salaries including the bonus and share based compensation. In addition,
the CODM examines the clinical trials expenses within the research and development operations.
SCHEDULE
OF SEGMENT REVENUE
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three months ended
June 30, | | |
Six months ended
June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Revenues | |
| 1,771 | | |
| 1,778 | | |
| 5,169 | | |
| 3,307 | |
| | |
| | | |
| | | |
| | | |
| | |
| Cost of Revenues: | |
| | | |
| | | |
| | | |
| | |
| Material and Labor | |
| 1,631 | | |
| 1,138 | | |
| 3,322 | | |
| 2,163 | |
| Other cost of revenues | |
| 302 | | |
| 327 | | |
| 849 | | |
| 539 | |
| Inventory write-off | |
| 612 | | |
| - | | |
| 1,085 | | |
| - | |
| Total Cost of Revenues | |
| 2,545 | | |
| 1,465 | | |
| 5,256 | | |
| 2,702 | |
| | |
| | | |
| | | |
| | | |
| | |
| Research and development (R&D) | |
| | | |
| | | |
| | | |
| | |
| Payroll and Benefits | |
| 1,282 | | |
| 1,120 | | |
| 2,882 | | |
| 1,974 | |
| Share based compensation | |
| 435 | | |
| 645 | | |
| 610 | | |
| 1,314 | |
| Clinical trials | |
| 972 | | |
| 1,125 | | |
| 2,473 | | |
| 2,287 | |
| Other R&D | |
| 1,606 | | |
| 944 | | |
| 3,093 | | |
| 2,318 | |
| Total Research and development | |
| 4,295 | | |
| 3,834 | | |
| 9,058 | | |
| 7,893 | |
| | |
| | | |
| | | |
| | | |
| | |
| Selling and marketing (S&M) | |
| | | |
| | | |
| | | |
| | |
| Payroll and Benefits | |
| 3,932 | | |
| 2,779 | | |
| 7,795 | | |
| 4,757 | |
| Share based compensation | |
| 543 | | |
| 595 | | |
| 1,124 | | |
| 812 | |
| Other S&M | |
| 746 | | |
| 798 | | |
| 1,482 | | |
| 1,353 | |
| Total Selling and marketing | |
| 5,221 | | |
| 4,172 | | |
| 10,401 | | |
| 6,922 | |
| | |
| | | |
| | | |
| | | |
| | |
| General and administrative (G&A) | |
| | | |
| | | |
| | | |
| | |
| Payroll and Benefits | |
| 1,365 | | |
| 1,729 | | |
| 3,172 | | |
| 3,309 | |
| Share based compensation | |
| 1,177 | | |
| 1,920 | | |
| 2,466 | | |
| 3,700 | |
| Other G&A | |
| 1,613 | | |
| 1,677 | | |
| 3,239 | | |
| 3,260 | |
| Total General and administrative | |
| 4,155 | | |
| 5,326 | | |
| 8,877 | | |
| 10,269 | |
| | |
| | | |
| | | |
| | | |
| | |
| Financial Income (expenses), net; | |
| 121 | | |
| (132 | ) | |
| 410 | | |
| 162 | |
| Segment net loss | |
| (14,324 | ) | |
| (13,151 | ) | |
| (28,013 | ) | |
| (24,317 | ) |
|